Regeneron Pharmaceuticals Aktie
| 744,41USD | -17,83USD | -2,34% |
WKN: 881535 / ISIN: US75886F1075
Aktionärsstruktur
| Inhaber | in % |
|---|---|
| Freefloat | 98,03 |
| Vanguard Group, Inc. (Subfiler) | 8,16 |
| The Vanguard Group, Inc. | 8,15 |
| Fidelity Management & Research Co. LLC | 7,37 |
| JPMorgan Investment Management, Inc. | 5,25 |
| Capital Research & Management Co. (World Investors) | 4,79 |
| State Street Corp. | 4,52 |
| Capital Research & Management Co. (World Investors) | 3,96 |
| Vanguard Total Stock Market ETF | 3,17 |
| Capital Research & Management Co. (International Investors) | 3,09 |
| BlackRock Fund Advisors | 2,92 |
| American Funds Growth Fund of America | 2,89 |
| Vanguard 500 Index Fund | 2,56 |
| Fidelity Contrafund | 2,46 |
| BlackRock Institutional Trust Co. NA | 2,16 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 8 100 | 9 123 | 10 368 | 11 851 | 13 450 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0,97 | 0,93 | 1,55 | 1,03 | 0,98 |
Bilanz (in Mio. USD) - Aktiva
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 7 689 | 9 779 | 14 015 | 15 884 | 19 479 |
| Summe Anlagevermögen | 7 116 | 7 384 | 11 420 | 13 389 | 13 651 |
| Summe Aktiva | 14 805 | 17 163 | 25 435 | 29 273 | 33 131 |
Bilanz (in Mio. USD) - Passiva
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Gesamtverschuldung/ -verbindlichkeiten | 714 | 2 696 | 2 700 | 2 701 | 2 703 |
| Summe Fremdkapital | 3 716 | 6 138 | 6 666 | 6 609 | 7 158 |
| Summe Eigenkapital | 11 090 | 11 025 | 18 769 | 22 664 | 25 973 |
| Summe Passiva | 14 805 | 17 163 | 25 435 | 29 273 | 33 131 |
Adresse
| 777 Old Saw Mill River Road, 10591-6707 Tarrytown | |
| Telefon | +1 (914) 847-7000 |
| Internet | http://www.regeneron.com |
Management
|
Alan Shuldiner
Vice President-Translational Genetics |
|
Andrew J. Murphy
Executive Vice President-Research |
|
Arthur Frederick Ryan
Independent Director |
|
Benjamin Drosman
SVP-Regulatory Compliance & Global Development |
|
Boaz Hirshberg
SVP-Clinical Sciences General Medicine |
|
Bob McCowan
Chief Information Officer & Senior VP-IT |
|
Bola Akinlade
Senior Vice President-Clinical Development |
|
Bonnie L. Bassler
Independent Director |
|
Christine A. Poon
Lead Independent Director |
|
Christine Childrose
Senior Vice President-Human Resources & Operations |
|
Christopher Robert Fenimore
Chief Financial Officer & Senior VP-Finance |
|
Christos Kyratsous
Senior Vice President-Research |
|
Craig B. Thompson
Independent Director |
|
Daniel P. van Plew
EVP, GM-Industrial Operations & Product Supply |
|
David Paul Schenkein
Director |
|
David Simon
Senior Vice President-Business Operations |
|
George Damis Yancopoulos
Co-Chairman & Co-President |
|
George L. Sing
Independent Director |
|
Gerald Underwood
Senior Vice President-Technical Operations |
|
Huda Y. Zoghbi
Independent Director |
|
Jason Pitofsky
Vice President & Controller |
|
John Calabro
Senior Vice President-Internal Auditor |
|
Johnathan M. Lancaster
Senior Vice President-Global Medical Affairs |
|
Joseph J. LaRosa
Secretary, Executive VP & General Counsel |
|
Joseph L. Goldstein
Independent Director |
|
Kathryn W. Guarini
Independent Director |
|
Kerry K. Reinertsen
Senior Vice President-Strategic Alliances |
|
Leonard Brooks
Treasurer & Senior Vice President |
|
Leonard S. Schleifer
Co-Chairman, Co-President & CEO |
|
Lori Morton
Senior Vice President-Research |
|
Lynn Macdonald
Senior Vice President-Research |
|
Marion McCourt
Executive Vice President-Commercial |
|
Mark Hudson
Head-Investor Relations |
|
Mark Volpe
Senior Vice President-Tax |
|
Maya Bermingham
Senior VP-Public Policy & Government Affairs |
|
Melissa Lozner
Chief Compliance Officer & Senior Vice President |
|
Michael S. Brown
Independent Director |
|
N. Anthony Coles
Independent Director |
|
Ned Braunstein
SVP-Regulatory Affairs & Global Patient Safety |
|
Neil Stahl
Executive VP-Research & Development |
|
Nouhad Husseini
Senior VP-Business Development |
|
Patrice Gilooly
Senior VP-Quality Assurance & Operations |
|
Ryan Crowe
Head-Investor Relations |
|
Sally A. Paull
Executive Vice President-Human Resources |
|
Smita Pillai
Chief Diversity, Equity & Inclusion Officer |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
